5 Stocks to Watch: Week of 10/27/2025
We’ve got a blockbuster list of stocks to watch in the coming week:
- Looking for a different type of AI play? Consider Vertiv Holdings (VRT)
- Lear Corp (LEA) is a hidden gem in the auto parts industry
- Why analysts we track are unanimously bullish about Tat Technologies (TATT)
- Northrop Grumman Corp (NOC) shows promise on post-earnings momentum
- Analysts are circling Biocryst Pharmaceuticals (BCRX) on bullish acquisition news
Missed last week’s picks? Get them here.
A note from our sponsors...
Sell Nvidia and replace it with WHAT?! The AI trade is running full throttle. But it won't last forever. It's not time to abandon AI stocks completely, but it IS time to prepare for the inevitable slowdown. Futurist Eric is giving away 7 free trade ideas in his "Sell This, Buy That" research package, where he reveals which market moves you need to make today (starting with getting rid of Nvidia stock.) Access these trade ideas here.1- Northrop Grumman Corp (NYSE: NOC)
Northrop Grumman is a big-time defense sector player that has its finger in many pots: aerospace technology, autonomous systems, and national security solutions. With the defense sector seeing elevated demand and the company posting strong earnings momentum, Northrop remains a core large-cap defense holding.
Zen Rating: B (Buy) — see full analysis
Recent Price: $596.48 — get current quote
Max 1-year forecast: $770.00
Why we're watching:
- Analyst support: Northrop is a perennial favorite among analysts; right now, it has 8 Strong Buy, 1 Buy, and 4 Hold recommendations in our system. See the ratings
- The current top forecast for NOC is $770, implying nearly 30% potential upside in the coming year.
- Recent analyst upgrades point to Northrop’s attractive value (21.42x PE vs. 28.24x industry average) and robust free cash flow.
- Industry ranking context: NOC ranks 6th out of 72 in its industry. See more Defense Industry stocks here.
- With a Zen Rating of B, NOC is in a class of stocks that have historically delivered 19.88% annual returns.
- Digging into the Component Grades, Northrop stands out with above-average B grades in several key areas, including Value, Momentum, and Growth. (See all 7 Zen Component Grades here)
2- Tat Technologies (NASDAQ: TATT)
This company provides something interesting: innovative thermal management, heat transfer, and maintenance services for commercial and military aerospace, with growing traction in electric aviation and defense upgrades. Recent contract wins and sector momentum have powered TATT’s shares to more than double in the past year.
Zen Rating: B (Buy) — see full analysis
Recent Price: $39.45 — get current quote
Max 1-year forecast: $56.00
Why we're watching:
- Analyst support: All 3 covering analysts rate TATT as a Strong Buy; consensus price target represents up to +42% upside. See the ratings
- Truist Securities' Michael Ciarmoli (a top 1% rated analyst) notes, "Investor sentiment about aircraft OEM production is increasing... Aftermarket demand trends continue to be supported by passenger travel strength, engine shop visits, and new aircraft supply chain challenges."
- Recent articles touting TATT highlight its positive trend and price strength, with features on its exposure to the fast-growing eVTOL market and 40% surge in the last three months.
- Industry ranking context: TATT is ranked 10th out of 72 in the Defense industry.
- With a Zen Rating of B, TATT is in the top 15% of stocks we track; Component Grades reveal above-average strength in Momentum, a key factor to help investors identify stocks on an upward trajectory that is likely to continue into the future. (See all 7 Zen Component Grades here)
3- Vertiv Holdings Co (NYSE: VRT)
Here’s a different type of AI play. As a provider of mission-critical infrastructure and services for data centers and communications, VRT perfectly positioned to capitalize on the exponential growth of AI and cloud computing. With robust organic order growth and strong earnings momentum, Vertiv’s upward trajectory continues to surprise the market.
Zen Rating: A (Strong Buy) — see full analysis
Recent Price: $171.59 — get current quote
Max 1-year forecast: $210.00
Why we're watching:
- Analyst support: VRT’s strong Q3 earnings beat and raised 2025 guidance have drawn bullish upgrades and fresh buy recommendations both from outlets like The Motley Fool and the analysts we track. See the ratings
- Recent analyst commentary highlights AI infrastructure as a powerful growth catalyst, with Seeking Alpha writing, "AI Infrastructure Continues To Fuel Growth."
- Also worth noting about VRT: organic orders are up 60% and diluted EPS up 122% year-over-year, with momentum outpacing sector giants.
- Industry ranking context: Vertiv is ranked 2nd out of 43 in the Electrical Equipment & Parts industry.
- As an A-rated (Strong Buy) stock, VRT is in an elite class of stocks that have delivered 32.52% annual returns. (VRT’s historical total return exceeds 1,600% since its 2018 debut.)
- In terms of Component Grades, highlights include As for Growth and Sentiment and Bs for Momentum and Financials. (See all 7 Zen Component Grades here)
4- Biocryst Pharmaceuticals (NASDAQ: BCRX)
This late-stage biotech targets rare diseases. Right now, the company is gaining analyst support on a proposed $700M acquisition, which could potentially derisk the pipeline and position BCRX for substantial revenue growth.
Zen Rating: A (Strong Buy) — see full analysis >
Recent Price: $6.63 — get current quote >
Max 1-year forecast: $30.00
Why we're watching:
- Analyst support: 4 Strong Buy, 5 Buy, 1 Hold (10 total). See the ratings
- TD Cowen researcher Stacy Ku just reinstated coverage with a Buy rating, citing the Astraia Therapeutics deal as a pipeline derisking catalyst; navenibart’s Phase 3 profile is attracting enthusiasm from key opinion leaders.
- Additional commentary: The Street projects BCRX’s 2026 EPS to return to positive territory, with consensus creating a striking forecast for 200%+ upside over the next year, backed by high analyst conviction.
- Industry ranking context: BCRX is a top-rated Biotech name with triple-digit price target upside potential.
- Component Grades: See detailed breakdown >
5- Lear Corp (NYSE: LEA)
Advanced automotive seating and electrical systems might not sound exciting, but they’re necessary — and demand is consistent. LEA maintains a strong dividend and trades at a significant value discount despite robust cash generation — check out this article for more info on why it’s a Strong Buy right now.
Zen Rating: A (Strong Buy) — see full analysis
Recent Price: $101.82 — get current quote
Max 1-year forecast: $136.00
Why we're watching:
- Analyst support: LEA earns 4 Strong Buy ratings from analysts we track, with the maximum forecast suggesting over 30% potential upside in the coming year. See the ratings here.
- LEA has Zen Rating of A — which means that a thorough review of 115 proprietary factors tied to outsized gains puts the stock in the top 5% of the more than 4,600 equities that we track. Better yet, LEA actually ranks in the top 3% — and is currently rated 134th overall on our list.
- Industry ranking context: Lear is #11 of 40 in the Auto Part industry (Industry Rating: A).
- Component Grades: LEA has a standout A grade for Value, and an impressive B rating from our AI factor, which sifts through mountains of data to detect subtle patterns that can predict stock success. (See all 7 Component Grades here)
What to Do Next?
Want to get in touch? Email us at news@wallstreetzen.com.
Keep Reading
See All News
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.